Market closed
Wave Life Sciences/$WVE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
$WVE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Singapore, Singapore
Employees
267
Website
WVE Metrics
BasicAdvanced
$1.8B
-
-$1.14
-1.21
-
Price and volume
Market cap
$1.8B
Beta
-1.21
52-week high
$15.84
52-week low
$3.50
Average daily volume
1M
Financial strength
Current ratio
1.901
Quick ratio
1.821
Long term debt to equity
13.224
Total debt to equity
18.172
Management effectiveness
Return on assets (TTM)
-34.04%
Return on equity (TTM)
-243.82%
Valuation
Price to revenue (TTM)
28.197
Price to book
12.61
Price to tangible book (TTM)
12.61
Price to free cash flow (TTM)
-10.659
Growth
Revenue change (TTM)
-37.29%
Earnings per share change (TTM)
36.72%
3-year revenue growth (CAGR)
3.30%
3-year earnings per share growth (CAGR)
-21.31%
What the Analysts think about WVE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
WVE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
WVE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
WVE News
AllArticlesVideos
Wave Life Sciences Is A Buy On Pipeline Prospects
Seeking Alpha·3 weeks ago
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
GlobeNewsWire·1 month ago
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $1.8B as of January 30, 2025.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of January 30, 2025.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -1.21. This means that it has an inverse relation to market volatility.